A Phase 1 interventional study of TAF in Hepatitis B Virus, sponsored by Gilead Sciences. Completed at 5 sites in 3 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-09.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing tenofovir alafenamide in Hepatitis B — 10 open to participants now, 12 under way, 1 of them phase 3. tenofovir alafenamide · Hepatitis B.
Among the 21 studies testing tenofovir alafenamide in Hepatitis B, this one is the 21st largest by enrollment, is the only one that started in 2014, is one of 2 in phase 1, and was the 2nd registered.
1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.
Browse Hepatitis B studies →10 of the 21 studies testing tenofovir alafenamide in Hepatitis B are open now, in 3 countries. Recruiting first, the newest first:
Guangzhou 8th People's Hospital · Sites in China
Ages 20–40 · Women only
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 18–65
Taichung Veterans General Hospital · Sites in Taiwan
Ages 20+
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 12–65
The Third Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 20–40 · Women only
By country, each count listing its studies:
tenofovir alafenamide: first FDA approval 2015 (GENVOYA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 145 across 756 interventional studies indexed under Hepatitis B.
Median enrollment 120 across the 21 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 21 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
24 studies in Hepatitis B by Gilead Sciences: none open now, none under way, none of them phase 3. Of 24 finished, 12 (50%) have results posted.
Among the 24 studies in Hepatitis B by Gilead Sciences, this one is the 18th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2014, is one of 4 in phase 1, and was the 23rd registered.
Gilead Sciences’s Hepatitis B studies by the year they started, since 2002.
3 of the studies testing tenofovir alafenamide in Hepatitis B that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06221657Yonsei UniversityClinical Trial for Non-inferiority and Safety of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in Patients With Hematologic Malignancies Who Require Prophylactic Hepatitis B Antiviral Treatment | 2026-12-01 |
| NCT07668934The Third Affiliated Hospital of Guangzhou Medical UniversityTAF in Early/Middle Pregnancy With CHB | 2027-03-30 |
| NCT07253220Sun Yat-sen UniversityTAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular Carcinoma | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies testing tenofovir alafenamide in Hepatitis B, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 24 in Hepatitis B:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the single-dose pharmacokinetics of tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) in participants with normal hepatic function and in participants with severe hepatic impairment.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with severe hepatic impairment will receive a single oral dose of TAF 25 mg on Day 1.
Drug: TAF
Participants with normal hepatic function will receive a single oral dose of TAF 25 mg on Day 1.
Drug: TAF
25 mg tablet administered orally
Pharmacokinetic (PK) Parameter: AUCinf of Tenofovir Alafenamide (TAF), Its Metabolite Tenofovir (TFV) and Free (Unbound) TAF
AUCinf is defined as the concentration of drug extrapolated to infinite time.
Time frame: Predose (≤5 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 12, 24, 36, 48, 60, 72, 96, 120, and 144 hours postdose on Day 1
PK Parameter: Cmax of TAF, Its Metabolite TFV and Free (Unbound) TAF
Cmax is defined as the maximum concentration of drug.
Time frame: Predose (≤5 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 12, 24, 36, 48, 60, 72, 96, 120, and 144 hours postdose on Day 1
PK Parameter: AUClast of TAF, Its Metabolite TFV and Free (Unbound) TAF
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
Time frame: Predose (≤5 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 12, 24, 36, 48, 60, 72, 96, 120, and 144 hours postdose on Day 1
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
TEAEs are events that meet one of the following criteria: any AEs with onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.
Time frame: Day 1 plus 30 days
Percentage of Participants Experiencing Treatment Emergent Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. These were graded as Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening. The most severe graded abnormality from all tests was counted for each participant.
Time frame: Day 1 plus 30 days
Participants were enrolled at study sites in Germany, New Zealand, and the United States. The first participant was screened on 22 December 2014. The last study visit occurred on 17 April 2015.
| Milestone | Severe Hepatic Impairment Group | Matched Normal Hepatic Function Group |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
AUCinf is defined as the concentration of drug extrapolated to infinite time.
| h*ng/mL | Severe Hepatic Impairment Group | Matched Normal Hepatic Function Group |
|---|---|---|
| TAF | 120.6 ± 33.96 | 228.2 ± 85.30 |
| TFV | 219.9 ± 118.70 | 304.0 ± 72.45 |
| Free (unbound) TAF | 42.8 ± 11.76 | 46.5 ± 17.78 |
Cmax is defined as the maximum concentration of drug.
| ng/mL | Severe Hepatic Impairment Group | Matched Normal Hepatic Function Group |
|---|---|---|
| TAF | 79.6 ± 39.31 | 176.0 ± 79.77 |
| TFV | 7.5 ± 3.95 | 7.6 ± 1.83 |
| Free (unbound) TAF | 29.9 ± 17.36 | 36.2 ± 18.38 |
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
| h*ng/mL | Severe Hepatic Impairment Group | Matched Normal Hepatic Function Group |
|---|---|---|
| TAF | 113.1 ± 30.85 | 225.7 ± 85.09 |
| TFV | 184.2 ± 99.86 | 256.7 ± 59.91 |
| Free (unbound) TAF | 41.7 ± 11.17 | 46 ± 17.75 |
TEAEs are events that meet one of the following criteria: any AEs with onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.
| percentage of participants | Severe Hepatic Impairment Group | Matched Normal Hepatic Function Group |
|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) | 40.0 | 30.0 |
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. These were graded as Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening. The most severe graded abnormality from all tests was counted for each participant.
| percentage of participants | Severe Hepatic Impairment Group | Matched Normal Hepatic Function Group |
|---|---|---|
| Grade 1 | 40.0 | 30.0 |
| Grade 2 | 40.0 | 30.0 |
| Grade 3 | 20.0 | 10.0 |
| Grade 4 | 0 | 0 |
Collected over Day 1 plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Severe Hepatic Impairment Group | 0/10 (0%) | 1/10 (10%) | 4/10 (40%) |
| Matched Normal Hepatic Function Group | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Event | Severe Hepatic Impairment Group | Matched Normal Hepatic Function Group |
|---|---|---|
| Hepatic failureHepatobiliary disorders | 1/10 | 0/10 |
| Event | Severe Hepatic Impairment Group | Matched Normal Hepatic Function Group |
|---|---|---|
| NauseaGastrointestinal disorders | 0/10 | 2/10 |
| HeadacheNervous system disorders | 1/10 | 2/10 |
| Abdominal distensionGastrointestinal disorders | 1/10 | 0/10 |
| VomitingGastrointestinal disorders | 0/10 | 1/10 |
| FatigueGeneral disorders | 0/10 | 1/10 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 1/10 | 0/10 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/10 | 0/10 |
| PruritusSkin and subcutaneous tissue disorders | 1/10 | 0/10 |
The Safety Analysis Set included all enrolled participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Severe Hepatic Impairment Group | Matched Normal Hepatic Function Group | Total |
|---|---|---|---|
| Mean | 57 ± 7.3 | 55 ± 9.3 | 56 ± 8.2 |
| Sex: Female, Male(Participants) | Severe Hepatic Impairment Group | Matched Normal Hepatic Function Group | Total |
|---|---|---|---|
| Female | 5 | 5 | 10 |
| Male | 5 | 5 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Severe Hepatic Impairment Group | Matched Normal Hepatic Function Group | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 4 | 7 |
| Not Hispanic or Latino | 7 | 6 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Severe Hepatic Impairment Group | Matched Normal Hepatic Function Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 10 | 9 | 19 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Severe Hepatic Impairment Group | Matched Normal Hepatic Function Group | Total |
|---|---|---|---|
| Germany | 1 | 3 | 4 |
| New Zealand | 2 | 2 | 4 |
| United States | 7 | 5 | 12 |
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
No publications or documents are linked to this record.
Ran from Dec 2014 to primary completion in Apr 2015, 3 months.
Results were first posted in Dec 2020, 5 years 7 months after primary completion.
Of 49 industry-sponsored phase 1 interventional studies under Hepatitis B, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 3 months is below that.
Counting every sponsor, half of 58 studies reached it within 14 months; a quarter within 7 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenofovir alafenamide